Muri iki gihe, umubyibuho ukabije wabaye icyorezo ku isi, kandi umubare w’umubyibuho ukabije wiyongereye mu bihugu byo ku isi.Ishami ry'Umuryango w'Abibumbye ryita ku Buzima, rivuga ko 13 ku ijana by'abantu bakuru ku isi bafite umubyibuho ukabije.Icy'ingenzi cyane, umubyibuho ukabije urashobora kurushaho gutera syndrome de metabolike, iherekejwe n’ibibazo bitandukanye nka diyabete yo mu bwoko bwa 2 mellitus, hypertension, steatohepatitis idafite inzoga (NASH), indwara zifata umutima na kanseri.
Muri Kamena 2021, FDA yemeje Semaglutide, imiti igabanya ibiro yakozwe na Novo Nordisk, nka Wegovy.Bitewe nigisubizo cyiza cyo kugabanya ibiro, umwirondoro mwiza wumutekano hamwe no gusunikwa nicyamamare nka Musk, Semaglutide yamenyekanye kwisi yose kuburyo bigoye kuyibona.Raporo y’imari ya 2022 ya Novo Nordisk, Semaglutide yinjije ibicuruzwa bigera kuri miliyari 12 z'amadolari mu 2022.
Vuba aha, ubushakashatsi bwasohotse mu kinyamakuru bwerekanye ko Semaglutide nayo ifite inyungu zitunguranye: kugarura imikorere y’uturemangingo twica umubiri (NK) mu mubiri, harimo n'ubushobozi bwo kwica kanseri ya kanseri, ibyo bikaba bidashingiye ku ngaruka zo kugabanya ibiro.Ubu bushakashatsi kandi ni inkuru nziza cyane ku barwayi bafite umubyibuho ukabije bakoresheje Semaglutide, byerekana ko uyu muti ufite inyungu zingenzi zishobora kugabanya ibyago bya kanseri usibye no kugabanya ibiro.Igisekuru gishya cyibiyobyabwenge, gihagarariwe na Semaglutide, kirahindura uburyo bwo kuvura umubyibuho ukabije kandi cyatunguye abashakashatsi n'ingaruka zacyo zikomeye.
None, ninde ushobora kubona ibiro byiza muri byo?
Ku nshuro yambere, itsinda ryagabanyije abantu bafite umubyibuho ukabije mu matsinda ane: abakeneye kurya byinshi kugirango bumve ko bahaze (inzara yubwonko), abarya ibiro bisanzwe ariko bakumva bashonje nyuma (inzara yo munda), abarya kugirango bahangane amarangamutima (inzara yamarangamutima), nabafite metabolisme itinda (metaboliste itinda).Iri tsinda ryasanze abarwayi bafite umubyibuho ukabije bishwe n'inzara bitabiriye neza iyi miti mishya igabanya ibiro kubera impamvu zitazwi, ariko abashakashatsi batekereje ko bishobora kuba biterwa n'uko GLP-1 itari hejuru, akaba ari yo mpamvu bongereye ibiro, bityo, ibiro byinshi igihombo hamwe na GLP-1 reseptor agonist.
Umubyibuho ukabije ubu ufatwa nk'indwara idakira, bityo iyi miti irasabwa kuvurwa igihe kirekire.Ariko ibyo bimara igihe kingana iki?Ntabwo bisobanutse, kandi iyi niyo nzira yo gushakishwa ubutaha.
Byongeye kandi, iyi miti mishya yo kugabanya ibiro yagize akamaro cyane kuburyo abashakashatsi bamwe batangiye kuganira kubyerekeranye nuburemere bwatakaye.Kugabanya ibiro ntabwo bigabanya ibinure gusa ahubwo binatera gutakaza imitsi, kandi guta imitsi byongera ibyago byindwara zifata umutima, osteoporose, nibindi bihe, ibyo bikaba bihangayikishije cyane abasaza nabafite uburwayi bwumutima.Aba bantu barebwa nicyo bita umubyibuho ukabije - gutakaza ibiro bifitanye isano nimpfu nyinshi.
Kubwibyo, amatsinda menshi yatangiye gukora ubushakashatsi ku ngaruka nke ziterwa no gukoresha iyi miti igabanya ibiro kugirango ikemure ibibazo bifitanye isano n’umubyibuho ukabije, nka apnea, indwara y’umwijima, na diyabete yo mu bwoko bwa 2, bidasaba byanze bikunze kugabanya ibiro.
Igihe cyo kohereza: Ukwakira-23-2023